Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Study of NKT2152, a HIF2a Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Complete Title: A PHASE 1/2, OPEN LABEL DOSE-ESCALATION AND EXPANSION TRIAL OF NKT2152, AN ORALLY ADMINISTERED HIF2α INHIBITOR, TO INVESTIGATE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY IN PATIENTS WITH ADVANCED CLEAR CELL RENAL CELL CARCINOMA
Trial Phase: I/II
Investigator: Evan Hall
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 Dose (RP2D) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I/II
Evan Hall
RG1122075
NCT05119335
A PHASE 1/2, OPEN LABEL DOSE-ESCALATION AND EXPANSION TRIAL OF NKT2152, AN ORALLY ADMINISTERED HIF2α INHIBITOR, TO INVESTIGATE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY IN PATIENTS WITH ADVANCED CLEAR CELL RENAL CELL CARCINOMA